MEDICONmm

Human Antibodies & Hybridomas

23-25 October 2023, The Richard Doll Building, University of Oxford, Oxford, UK

Sponsored by the International Journal Human Antibodies
In association with the Integrative Medical Sciences Association 

The HAH 2023 scientific programme will have a broadened scope from previous events in the series  with the addition of some new topic areas outlined in the scope section below. As usual the scientific programme will include keynote lectures, contributed oral papers and poster presentations emphasising all key aspects of human antibody technologies, applications and engineering.

Programme Chairman:
Professor Mark Glassy (UCSD Moores Cancer Center, San Diego, California, USA) 

Chris Scott (The Queen’s University, Belfast, Northern Ireland, UK)
Jim Larrick (Panorama Research Inc., USA)
Alois Lang (GeNeuro SA, Geneva, Switzerland)
David P. Humphreys (UCB, Slough, UK)
Markus Enzelberger (MorphoSys AG, Martinsried, Germany)
Eszter Nagy (Arsanis GmbH, Vienna, Austria)
Sachdev Sidhu (University of Toronto, Canada)
Neil Brewis (F-star, Cambridge, UK)
Paul Kerr (Fusion Antibodies, Belfast, Northern Ireland, UK)
David Naor (The Hebrew University, Jerusalem, Israel)
Lynn MacDonald (Regeneron Pharmaceuticals, Tarrytown, New York, USA)
Maria Groves (Medimmune, Cambridge, UK)
Hermann Katinger and Dietmar Katinger (Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria)
Rick Buick (Fusion Antibodies, Belfast, Northern Ireland, UK)
Geoff Hale (mAbsolve Ltd/ University of Oxford, Oxford, UK)
Ian Wilkinson (mAbsolve Ltd, Durham/Oxford, UK)

The scope of the HAH 2023 conference falls broadly into the following main session categories:

  • Infectious Diseases
  • Autoimmunity
  • Molecular Biology
  • Emerging Technologies
  • Clinical Applications
  • Therapeutic Antibodies
  • Cancer
  • Anti-Infective Antibodies
  • Intellectual Property & Legal Issues

For this and future meetings the scope is being expanded to include sessions on:

  • Formulation
  • Oral Delivery
  • Combination Therapy
  • Validity of Animal Models Peptide Drugs
  • Immunotherapy of Cancer & Autoimmunity

HAH 2023 will also have a special focus on Updates on Antibody-Drug Conjugates.

Invited Keynote Speaker:
Paul Parren (Lava Therapeutics, Utrecht, The Netherlands)